Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top ...

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year. In an interview at the JP Morgan Healthcare Conference in San Francisco ...

TikTok CEO Shou Zi Chew plans to attend President-elect Donald Trump's inauguration on Monday as the company confronts a new law with a looming deadline requiring it to sell to a non-Chinese firm ...

UnitedHealth Group CEO Andrew Witty also acknowledged the U.S. health care system is confusing and must improve, citing high prices of medical services as the "root cause" of the nation's health ...

TikTok CEO Shou Zi Chew will attend President-elect Trump’s inauguration Monday, one day after a potential ban of the video sharing platform could take effect in the U.S., according to a source ...

who ran the big drugmaker GlaxoSmithKline for nearly a decade before joining UnitedHealth Group’s management team to run Optum before being elevated to CEO of UnitedHealth. “OptumRx alone ...

The CEO of GSK (GlaxoSmithKline) wasn’t asked specifically about the prospect of vaccines under Trump, but Emma Walmsley did sing their praises. “The reality is there is no better return on ...

who was previously CEO of British drugmaker GlaxoSmithKline (GSK.L), opens new tab. UnitedHealth, which operates the biggest health insurer in the United States, a large pharmacy benefit manager ...

While CEO Robert Michael said during the conference that the pharma ... Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay ...